Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma

Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma

Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. Patients and Methods: We coordinated a first-in-kind phase II clinical trial of the CDK4/6i abemacic...

Full description

Bibliographic Details
Main Authors: Gleason, Caroline E., Dickson, Mark A., Klein, Mary E. (Dooley), Antonescu, Cristina R., Gularte-Mérida, Rodrigo, Benitez, Marimar, Delgado, Juliana I., Kataru, Raghu P., Tan, Mark Wei Yi, Bradic, Martina, Adamson, Travis E., Seier, Kenneth, Richards, Allison L., Palafox, Marta, Chan, Eric, D'Angelo, Sandra P., Gounder, Mrinal M., Keohan, Mary Louise, Kelly, Ciara M., Chi, Ping, Movva, Sujana, Landa, Jonathan, Crago, Aimee M., Donoghue, Mark T. A., Qin, Li-Xuan, Serra, Violetta, Turkekul, Mesruh, Barlas, Afsar, Firester, Daniel M., Manova-Todorova, Katia, Mehrara, Babak J., Kovatcheva, Marta, Tan, Nguan Soon, Singer, Samuel, Tap, William D., Koff, Andrew
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2024
Subjects:
Medicine, Health and Life Sciences
Dedifferentiated liposarcoma
DNA microarray
Online Access:https://hdl.handle.net/10356/180081

Internet

https://hdl.handle.net/10356/180081

Similar Items